Moderna (MRNA) Cash & Current Investments (2017 - 2026)

Moderna (MRNA) has reported Cash & Current Investments for 10 consecutive years, with $5.1 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Current Investments changed 0.14% year-over-year to $5.1 billion in Q2 2026; TTM through Jun 2026 was $5.1 billion, a 0.14% change from a year earlier, with the FY2025 full-year figure at $5.8 billion, down 17.45% from the prior year.
• Cash & Current Investments was $5.1 billion for Q2 2026 at Moderna, down from $5.2 billion in the prior quarter.
• Over five years, Cash & Current Investments peaked at $10.1 billion in Q1 2022 and troughed at $4.5 billion in Q3 2025.
• A 5-year average of $7.4 billion and a median of $7.7 billion in 2022 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments jumped 30.77% in 2022 and slumped 39.55% in 2025, its largest moves.
• Over 5 years, Cash & Current Investments stood at $9.9 billion in 2022, then decreased by 13.11% to $8.6 billion in 2023, then retreated by 18.35% to $7.0 billion in 2024, then dropped by 17.45% to $5.8 billion in 2025, then slipped by 11.4% to $5.1 billion in 2026.
• The last three Cash & Current Investments figures came in at $5.1 billion (Q2 2026), $5.2 billion (Q1 2026), and $5.8 billion (Q4 2025), per Business Quant data.